Anzeige
Mehr »
Montag, 17.08.2026 - Börsentäglich über 12.000 News
100%iger Erfolg - in 70 Tagen Querschnittslähmung geheilt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DNSU | ISIN: CA67059R1091 | Ticker-Symbol: J90
Tradegate
17.08.26 | 07:30
0,318 Euro
+7,07 % +0,021
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
NUREXONE BIOLOGIC INC Chart 1 Jahr
5-Tage-Chart
NUREXONE BIOLOGIC INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,2970,32110:43
0,2980,31710:40

Aktuelle News zur NUREXONE BIOLOGIC Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
NUREXONE BIOLOGIC Aktie jetzt für 0€ handeln
09:30KURSEXPLOSION bei Nurexone Biologic: Partnerschaft löst Anstieg um 6,45% aus
FrNurexone Biologic Inc: Nurexone releases preclinical data supporting ExoPTEN15
FrNurExone Biologic Inc: NurExone Reports New Preclinical Tissue-Analysis Data Supporting Potential Neuroprotective Effect of ExoPTEN in Acute Spinal Cord Injury Animal Model543TORONTO and HAIFA, Israel, Aug. 14, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. ("NurExone" or the "Company") (TSXV: NRX, OTCQB: NRXBF, FSE: J90), a biotechnology company developing exosome-based...
► Artikel lesen
DoNurexone Biologic Inc: Nurexone Biologic signs MOU with Made Scientific22
MiNurExone Biologic Inc: NurExone Announces Binding MOU with Made Scientific for U.S. GMP Manufacturing and Commercial Supply Partnership141TORONTO and HAIFA, Israel, Aug. 13, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. ("NurExone" or the "Company") (TSXV: NRX, OTCQB: NRXBF, FSE: J90), a biotechnology company developing exosome-based...
► Artikel lesen
31.07.Nurexone Biologic Inc: Nurexone to apply Novasign platform for production28
28.07.NurExone Biologic Inc: Corporate Updates - NurExone appoints Mr. David Stolick to the Board of Directors276TORONTO, Ontario and HAIFA, Israel, July 29, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biopharmaceutical company developing...
► Artikel lesen
01.07.Nurexone Biologic Inc: Nurexone Biologic closes $627,795 private placement66
30.06.NurExone Biologic Inc: NurExone Announces Closing of Non-Brokered Private Placement31
25.06.Nurexone Biologic Inc: Nurexone unit signs MOU re exosome product distribution33
24.06.NurExone Biologic Inc: Exo-Top, NurExone's wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico448TORONTO, Ontario and HAIFA, Israel, June 25, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biopharmaceutical company developing...
► Artikel lesen
24.06.EXCLUSIVE: NurExone Targets Mexico Wellness Market With Exosome Supply Agreement (UPDATED)3
24.06.EXCLUSIVE: France Based NurExone Targets Mexico Wellness Market With Exosome Supply Agreement4
05.06.NurExone Biologic GAAP EPS of -$0.0374
01.06.NurExone Biologic Inc: NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update562TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biopharmaceutical company developing...
► Artikel lesen
19.05.NurExone Biologic Inc: NurExone Receives Notice of Patent Grant in South Korea Covering ExoPTEN Technology411TORONTO, Ontario and HAIFA, Israel, May 19, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biopharmaceutical company developing...
► Artikel lesen
28.04.Nurexone Biologic Inc: Nurexone granted patent by IP Australia49
27.04.NurExone Biologic Inc: Australian Patent Granted to NurExone Covering Stem Cell-Derived Exosome Production653TORONTO, Ontario and HAIFA, Israel, April 27, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biopharmaceutical company developing...
► Artikel lesen
16.04.NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update682TORONTO, Ontario and HAIFA, Israel, April 16, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biopharmaceutical company developing...
► Artikel lesen
16.04.Nurexone Biologic Inc: Nurexone Biologic 1,295,222-share private placement36
Weiter >>
44 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,5